Effects of transdermal scopolamine upon psychological test performance at sea
- PMID: 4029247
- DOI: 10.1007/BF00544360
Effects of transdermal scopolamine upon psychological test performance at sea
Abstract
The effects of transdermal scopolamine upon objective psychological performance assessments and self reports of feeling states, were investigated with volunteer subjects at sea. Scopolamine and placebo patches were administered on consecutive days in a counterbalanced order. Psychological performance was assessed 24 h following each transdermal patch. Choice reaction time and code substitution performance levels were not significantly changed, but letter cancellation errors were significantly more frequent following transdermal scopolamine. Transdermal scopolamine caused significantly more reports of dry mouth. More subjects were also unable to undertake the performance tests following scopolamine than placebo, due to difficulties in focusing on the test materials. However despite deleterious side effects with some personnel, others responded positively to the scopolamine patch. As noted by other workers, responses to the transdermal scopolamine patch seem to be quite variable.
Similar articles
-
Transdermal scopolamine for prevention of motion sickness : clinical pharmacokinetics and therapeutic applications.Clin Pharmacokinet. 2006;45(6):543-66. doi: 10.2165/00003088-200645060-00001. Clin Pharmacokinet. 2006. PMID: 16719539 Review.
-
The effects of dimenhydrinate, cinnarizine and transdermal scopolamine on performance.J Psychopharmacol. 2001 Sep;15(3):167-72. doi: 10.1177/026988110101500311. J Psychopharmacol. 2001. PMID: 11565623 Clinical Trial.
-
The effects of transdermal scopolamine on simulated ship navigation and attention/reaction time.Int J Occup Environ Health. 2008 Oct-Dec;14(4):250-6. doi: 10.1179/oeh.2008.14.4.250. Int J Occup Environ Health. 2008. PMID: 19043911 Clinical Trial.
-
Transdermal scopolamine in the prevention of motion sickness at sea.Clin Pharmacol Ther. 1981 Mar;29(3):414-9. doi: 10.1038/clpt.1981.57. Clin Pharmacol Ther. 1981. PMID: 7009021 Clinical Trial.
-
Transdermal scopolamine: a review of its effects upon motion sickness, psychological performance, and physiological functioning.Aviat Space Environ Med. 1989 Jan;60(1):1-9. Aviat Space Environ Med. 1989. PMID: 2647072 Review.
Cited by
-
Transdermal scopolamine for prevention of motion sickness : clinical pharmacokinetics and therapeutic applications.Clin Pharmacokinet. 2006;45(6):543-66. doi: 10.2165/00003088-200645060-00001. Clin Pharmacokinet. 2006. PMID: 16719539 Review.
-
The effects of transdermal scopolamine and four dose levels of oral scopolamine (0.15, 0.3, 0.6, and 1.2 mg) upon psychological performance.Psychopharmacology (Berl). 1986;89(3):347-54. doi: 10.1007/BF00174373. Psychopharmacology (Berl). 1986. PMID: 3088662 Clinical Trial.
-
Promethazine, scopolamine and cinnarizine: comparative time course of psychological performance effects.Psychopharmacology (Berl). 1987;92(4):513-9. doi: 10.1007/BF00176487. Psychopharmacology (Berl). 1987. PMID: 3114803 Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials